#M&A – Page 2 – HEALTHCARE INSIGHTS

Key Development Tokyo-headquartered biopharmaceutical enterprise Chugai Pharmaceutical Co., Ltd. (TYO: 4519)—a member of the Roche Group—has officially entered into an... Read more

Tag: #M&A

Biopharmaceutical Formulation & Drug Delivery Innovation: Novartis Secures Multi-Target Global Licensing Deal Worth Up to $3.22 Billion for Alteogen’s Hybrozyme™ (ALT-B4) Platform – Enabling Subcutaneous Delivery for Core Biologics

Precision Oncology & Next-Gen ADC Platforms: Genentech and DualityBio Enter Potential $1 Billion+ Global Alliance to Pioneer Novel Payload-Linker Platforms Overcoming Topoisomerase Inhibitor Resistance

Consumer Healthcare & FMCG Mega-Merger: Kimberly-Clark Requests European Commission Clearance for $40 Billion Acquisition of Kenvue to Form $32 Billion Powerhouse with $2.1 Billion Annual Cost Synergies

Biopharmaceutical CDMO Consolidation: Samsung Biologics Formally Initiates $1.80 Billion Public Takeover Offer for Swiss Peptide Specialist PolyPeptide Group to Solidify Global GLP-1 Supply Dominance

MedTech Cybersecurity & Supply Chain Disruption: Boston Scientific Discloses Cyber Incident Impacting Global Order Processing and Shipments – Wall Street Models Up to 700 bps Q3 Revenue Exposure

Global Infectious Disease Licensing: Chugai Grants GSK Exclusive Worldwide License for Investigational Anti-Dengue Antibody AID351

Targeting Undruggable Ion Channels: Eli Lilly and OmniAb Enter Global Research Collaboration and License Agreement Valued Up to $370 Million for Next-Generation Antibody Therapeutics

Rare Skeletal Disease M&A: BioMarin Acquires Alesta Therapeutics for Up to $490 Million to Challenge AstraZeneca’s Hypophosphatasia Franchise with Oral Asset ALE1

Rare Genetic Dermatology Licensing: LEO Pharma Secures Worldwide Exclusive Rights to Oral Dersimelagon for Up to $435 Million from Mitsubishi Tanabe Pharma

Facebook

Map

Online Members